Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Martin Sean | SVP and General Counsel | Nov 02 | Option Exercise | 50.77 | 47,001 | 2,386,241 | 86,641 | Nov 04 04:05 PM | Martin Sean | SVP and General Counsel | Nov 02 | Sale | 78.67 | 47,001 | 3,697,794 | 39,640 | Nov 04 04:05 PM | FORSYTH JOHN D | Director | Sep 14 | Option Exercise | 31.26 | 310 | 9,691 | 34,279 | Sep 15 04:07 PM | FORSYTH JOHN D | Director | Sep 14 | Sale | 83.59 | 310 | 25,913 | 33,969 | Sep 15 04:07 PM | GAVIN JAMES R III | Director | Aug 03 | Option Exercise | 38.14 | 14,899 | 568,289 | 54,407 | Aug 05 05:39 PM | GAVIN JAMES R III | Director | Aug 03 | Sale | 86.41 | 14,899 | 1,287,366 | 39,508 | Aug 05 05:39 PM | Accogli Giuseppe | SVP, President, Americas | Jun 19 | Option Exercise | 50.23 | 70,722 | 3,552,303 | 138,861 | Jun 23 04:00 PM | Accogli Giuseppe | SVP, President, Americas | Jun 19 | Sale | 85.00 | 72,341 | 6,148,985 | 66,520 | Jun 23 04:00 PM | FORSYTH JOHN D | Director | Jun 15 | Option Exercise | 31.26 | 1,500 | 46,890 | 35,398 | Jun 17 04:02 PM | FORSYTH JOHN D | Director | Jun 15 | Sale | 82.95 | 1,500 | 124,425 | 33,898 | Jun 17 04:02 PM | Franzi Cristiano | SVP, President, EMEA | Jun 08 | Option Exercise | 62.23 | 46,600 | 2,899,918 | 85,688 | Jun 10 04:17 PM | Franzi Cristiano | SVP, President, EMEA | Jun 08 | Sale | 87.64 | 46,600 | 4,083,879 | 39,088 | Jun 10 04:17 PM | Frye Andrew | SVP, President, APAC | Jun 03 | Sale | 91.00 | 3,742 | 340,522 | 16,216 | Jun 05 04:02 PM | Mason Jeanne K | SVP, Human Resources | Apr 27 | Option Exercise | 28.97 | 47,146 | 1,365,820 | 163,485 | Apr 29 04:03 PM | Mason Jeanne K | SVP, Human Resources | Apr 27 | Sale | 93.13 | 47,146 | 4,390,608 | 116,339 | Apr 29 04:03 PM | HELLMAN PETER S | Director | Apr 01 | Option Exercise | 24.27 | 4,320 | 104,846 | 28,620 | Apr 03 03:59 PM | STROUCKEN ALBERT P L | Director | Apr 01 | Option Exercise | 24.27 | 4,320 | 104,846 | 34,018 | Apr 03 04:00 PM | STROUCKEN ALBERT P L | Director | Apr 01 | Sale | 79.64 | 4,320 | 344,027 | 29,698 | Apr 03 04:00 PM | HELLMAN PETER S | Director | Apr 01 | Sale | 79.66 | 4,320 | 344,142 | 24,300 | Apr 03 03:59 PM | Martin Sean | SVP and General Counsel | Mar 30 | Buy | 82.19 | 9,780 | 803,818 | 39,504 | Apr 01 04:17 PM | FORSYTH JOHN D | Director | Mar 18 | Option Exercise | 31.26 | 1,500 | 46,890 | 33,138 | Mar 19 04:51 PM | FORSYTH JOHN D | Director | Mar 18 | Sale | 76.70 | 1,500 | 115,050 | 31,638 | Mar 19 04:51 PM |
|